Search Results

Study of Autopsy Registry Evaluates Causes of Early Stent Thrombosis in ACS Patients

April 23, 2014—Masataka Nakano, MD, et al published findings from an ex vivo human autopsy study to determine causes of early stent thrombosis in patients presenting with acute coronary syndrome (ACS).

Three-Year Data Presented for OrbusNeich's Combo Dual-Therapy Stent

May 23, 2014—OrbusNeich announced that long-term results from the REMEDEE trial of the company’s Combo dual-therapy stent were presented at a symposium during the EuroPCR 2014 congress held May 20–23, in Paris, France.

Emblok Evaluates Whole-Body Embolic Protection System for TAVR Procedures

October 8, 2024—Emblok announced that it has enrolled the first 50 patients in a clinical trial to evaluate the performance and treatment effect of its Emblok embolic protection system (EPS).

Evalve's MitraClip EVEREST Data Presented at TCT

September 22, 2009—Evalve, Inc. (Menlo Park, CA) announced that data were presented from the company's EVEREST (Endovascular Valve Edge-to-Edge Repair Study) registries studying reduction in mitral regurgitation (MR) at 12 months after percutaneous mitral valve repair with the MitraClip system.

Enrollment Completed in CLEAN-TAVI Trial of Claret Medical's Cerebral Protection System

September 4, 2014—Claret Medical, Inc. announced completion of enrollment in the CLEAN-TAVI (Claret Embolic Protection and Transcatheter Aortic Valve Implantation) clinical trial studying its filter-based cerebral protection system (CPS).

FDA Approves CeloNova's Cobra PzF Stent System

March 1, 2017—CeloNova BioSciences, Inc. announced US Food and Drug Administration approval of its Cobra PzF polyzene-F nanothin polymer-coated coronary stent system.

Abbott to Acquire Evalve; MitraClip's EVEREST Data Presented at TCT

September 10, 2009—Abbott Vascular (Santa Clara, CA) announced a definitive agreement to acquire the outstanding equity of Evalve, Inc. (Menlo Park, CA).

Enrollment Begins in REMEDEE Trial of OrbusNeich's Combo DES

December 1, 2009—OrbusNeich, Inc. (Fort Lauderdale, FL) announced the initiation of patient enrollment in the REMEDEE (Randomized Evaluation of an Abluminal Sirolimus-Coated Bio-Engineered Stent) clinical trial of the company's Combo bioengineered sirolimus-eluting stent.

OrbusNeich's Combo Dual-Therapy Stent Receives CE Mark Approval

May 27, 2013—OrbusNeich (Fort Lauderdale, FL) announced CE Mark approval and the launch of the Combo dual-therapy stent for the treatment of coronary artery disease.

Results of CLEAN-TAVI Support Use of Claret's Cerebral Protection System

September 13, 2014—Axel Linke, MD, presented results of the CLEAN-TAVI trial at the 26th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, DC.

Analysis Published of Embolic Debris Captured During TAVR Using Claret Medical's Montage 2 System

May 20, 2013—Claret Medical, Inc. (Santa Rosa, CA) announced that Nicolas M. Van Mieghem, MD, et al published a study on the histopathology of embolic debris captured during transcatheter aortic valve replacement (TAVR) using the company's Montage 2 dual-filter embolic protection system. The study is available online ahead of print in Circulation.